SCHEMBL469153

SCHEMBL469153

Cc1cncc(-c2cnc(-c3ccccc3)c(C)n2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 3/20 0.47
HCRTR2 O43614 3/20 0.47
RAB9A P51151 2/20 0.43
NPC1 O15118 1/20 0.43
PDGFRB P09619 1/20 0.43
KDR P35968 1/20 0.43
FLT3 P36888 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
CYP11B1 P15538 8/20 0.43
CYP11B2 P19099 8/20 0.43
CYP3A4 P08684 1/20 0.43
ADORA1 P30542 1/20 0.40
ATR Q13535 1/20 0.40
KDM4E B2RXH2 2/20 0.38
ALDH1A1 P00352 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MEN1 O00255 1/20 0.38
POLB P06746 1/20 0.38
MAPT P10636 1/20 0.38
PKM P14618 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2912954 0.84 SMN1; SMN2 (0.53) RAB9ANPC1PDGFRBKDRFLT3
SCHEMBL7877771 0.82 HCRTR1 (0.57) HCRTR1HCRTR2CYP11B1CYP11B2CYP3A4
SCHEMBL12539180 0.80 SMN1; SMN2 (0.50) RAB9ANPC1PDGFRBKDRFLT3
SCHEMBL438304 0.78 HCRTR2 (0.61) HCRTR1HCRTR2SMN1; SMN2CYP3A4ATR
SCHEMBL2647551 0.74 CYP2A6 (0.55) CYP11B1CYP11B2CYP3A4
SCHEMBL11978672 0.73 CYP2A6 (0.53) CYP11B1CYP11B2CYP3A4
SCHEMBL20848298 0.72 CYP11B2 (0.38) HCRTR1HCRTR2CYP11B1CYP11B2CYP3A4
SCHEMBL20848324 0.72 NOS1 (0.40) HCRTR1HCRTR2CYP11B1CYP11B2CYP3A4
SCHEMBL15052370 0.71 RAB9A (0.51) RAB9ANPC1PDGFRBKDRFLT3
SCHEMBL3423404 0.71 CYP11B1 (0.49) RAB9ACYP11B1CYP11B2CYP3A4KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120065205-A1 PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS MERCK SHARP & DOHME CORP. 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065205-A1 PYRAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY5R HCRTR1 2/4885HCRTR2 1/4885RAB9A 2717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.